ResearcherUniversity of North Carolina at Chapel HillNo recent work listed

Rihe Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0793-9064; OpenAlex author ID A5053322097; NIH RePORTER profile ID 7040376. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 1
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2016: 1 grant · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper

Papers 2

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Co-author DOI 10.1016/j.tranon.2020.100856 ↗
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. Co-author DOI 10.1021/acsnano.7b01786 ↗

Grants 1

Novel Single Domain Antibodies with Multivalency and Multispecificity R01CA157738 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Manisit Das · 2 shared papers, 2017–2020 · strength 0.19
- Paper Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. DOI 10.1016/j.tranon.2020.100856 ↗
- Paper Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. DOI 10.1021/acsnano.7b01786 ↗
Leaf Huang · 2 shared papers, 2017–2020 · strength 0.19
- Paper Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. DOI 10.1016/j.tranon.2020.100856 ↗
- Paper Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. DOI 10.1021/acsnano.7b01786 ↗
Jingjing Li · 1 shared paper, 2017 · strength 0.07
- Paper Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. DOI 10.1021/acsnano.7b01786 ↗
Lei Miao · 1 shared paper, 2017 · strength 0.07
- Paper Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. DOI 10.1021/acsnano.7b01786 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.